KEYMED BIOSCIENCES -0001 Asset Resilience Ratio
KEYMED BIOSCIENCES -0001 asset resilience ratio. KEYMED BIOSCIENCES -0001 (64Z) has an Asset Resilience Ratio of 33.68% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of KEYMED BIOSCIENCES -0001 to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of KEYMED BIOSCIENCES -0001 (2021–2025)
Asset resilience ratio of KEYMED BIOSCIENCES -0001 from 2021 to 2025. This chart shows how KEYMED BIOSCIENCES -0001's Asset Resilience Ratio has changed over time. Read KEYMED BIOSCIENCES -0001 (64Z) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down KEYMED BIOSCIENCES -0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see KEYMED BIOSCIENCES -0001 asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.42 Billion | 33.68% |
| Total Liquid Assets | €1.42 Billion | 33.68% |
Asset Resilience Insights
- Very High Liquidity: KEYMED BIOSCIENCES -0001 maintains exceptional liquid asset reserves at 33.68% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
KEYMED BIOSCIENCES -0001 Industry Peers by Asset Resilience Ratio
Compare KEYMED BIOSCIENCES -0001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
KEYMED BIOSCIENCES -0001 Asset Resilience Ratio by Year (2021–2025)
KEYMED BIOSCIENCES -0001 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for KEYMED BIOSCIENCES -0001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 33.68% | €1.42 Billion ≈ $1.66 Billion |
€4.22 Billion ≈ $4.93 Billion |
-12.44pp |
| 2024-12-31 | 46.12% | €1.74 Billion ≈ $2.03 Billion |
€3.77 Billion ≈ $4.40 Billion |
-1.99pp |
| 2023-12-31 | 48.11% | €1.87 Billion ≈ $2.18 Billion |
€3.88 Billion ≈ $4.54 Billion |
-17.28pp |
| 2022-12-31 | 65.39% | €2.57 Billion ≈ $3.01 Billion |
€3.93 Billion ≈ $4.60 Billion |
+14.45pp |
| 2021-12-31 | 50.93% | €2.00 Billion ≈ $2.34 Billion |
€3.93 Billion ≈ $4.60 Billion |
-- |
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis;… Read more